(Avg 5.0 based on 1 rating)
1 / 1 vote
Dr. Raturi Vijay Parshuram Verified by iCliniq
MD RADIOTHERAPY., DNB RADIOTHERAPY
Professional Bio:
Dr. Raturi Vijay Parshuram is a Radiation Oncologist with seven years of clinical experience. He completed his MD in Radiotherapy from the King George's Medical University, Lucknow, India, in 2016 and... Read More
Experience
7+ Yrs
Languages
English
Patients
Helped 1000 patients
Fee
Query : $49
Phone/Video : $59
Patient's Feedback
"Thank"
Professional Bio
Dr. Raturi Vijay Parshuram is a Radiation Oncologist with seven years of clinical experience. He completed his MD in Radiotherapy from the King George's Medical University, Lucknow, India, in 2016 and DNB in Radiotherapy at the Directorate of National Board, Delhi. Presently, he is working at the National Cancer Center Hospital East, Japan, for past two years. He treats all cancer subsites using photon and proton therapy. His main focus or research area is using proton therapy for head and neck and gastrointestinal malignancy.
Academics & Trainings
MD RADIOTHERAPY
King George's Medical University, Lucknow
2016
DNB RADIOTHERAPY
Directorate Of National Board, Delhi
2018
Awards & Publications
Dr. Raturi Vijay Parshuram is a Visiting Scientist (Particle Therapy and Translational Research) at National Cancer Center Hospital East, Chiba, Japan, and a research associate (Particle therapy) in the National Cancer Center Hospital East, Chiba, Japan. Publications: a) Multiple Inherited Schwannomas, Meningiomas, and Ependymomas Syndrome in an Adult Patient. b) A Prospective Randomized Comparison of Concurrent Chemoradiation with Neoadjuvant and Adjuvant Chemotherapy with Concurrent Chemoradiation Alone for Locally Advanced Carcinoma Cervix. c) Affiliation of XRCC-1 Gene Arg194Trp polymorphism in alcohol and tobacco substance users and loco-regionally progressed LSCC. d) A Prospective Study Comparing Oxaliplatin & 5-Fu with Gemcitabine & Cisplatin in Advanced Stage Carcinoma Gall Bladder. e) A Prospective Randomized Comparison of Concurrent Chemoradiation with Neoadjuvant and Adjuvant Chemotherapy with Concurrent Chemoradiation Alone for Locally Advanced Carcinoma Cervix. f) Hypofractionated proton beam therapy for centrally located lung cancer. g) Impact of Proton Beam Irradiation of an Anatomic Subsegment of the Liver for Hepatocellular Carcinoma. h) Could excision repair cross-complementing group-1mRNA expression from peripheral blood lymphocytes predict locoregional failure with cisplatin chemoradiation for locally advanced laryngeal cancer? i) Prospective evaluation of XRCC‐1 Arg194Trp polymorphism as bio‐predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatin‐based chemoradiation. j) Efficacy and safety of accelerated fractionated radiotherapy without elective nodal irradiation for T3N0 glottic cancer without vocal cord fixation. k) Prospective evaluation of the setup errors and their impact on safety margin for cervical cancer pelvic conformal radiotherapy. l) Treatment patterns and outcomes change in early-stage non-small cell lung cancer in octogenarians and older: a SEER database analysis.